[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 28000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 61, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 6428574, "exercisedValue": 0, "unexercisedValue": 50993104}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 65, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 3007214, "exercisedValue": 0, "unexercisedValue": 1401880}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 3327225, "exercisedValue": 0, "unexercisedValue": 7193319}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 57, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 3174030, "exercisedValue": 0, "unexercisedValue": 4835902}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 52, "title": "Executive Vice President of Research & Development", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 4095677, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 56, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Skellenger", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard Y. Chang M.D., Ph.D.", "title": "Senior VP of Global Research & Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 3, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 293.38, "open": 295.49, "dayLow": 293.3501, "dayHigh": 297.8851, "regularMarketPreviousClose": 293.38, "regularMarketOpen": 295.49, "regularMarketDayLow": 293.3501, "regularMarketDayHigh": 297.8851, "dividendRate": 9.52, "dividendYield": 3.24, "exDividendDate": 1755820800, "payoutRatio": 0.7572, "fiveYearAvgDividendYield": 3.03, "beta": 0.48, "trailingPE": 24.036007, "forwardPE": 14.209966, "volume": 1643969, "regularMarketVolume": 1643969, "averageVolume": 2390388, "averageVolume10days": 1875630, "averageDailyVolume10Day": 1875630, "bid": 278.84, "ask": 294.24, "bidSize": 1, "askSize": 3, "marketCap": 158127685632, "fiftyTwoWeekLow": 253.3, "fiftyTwoWeekHigh": 339.17, "priceToSalesTrailing12Months": 4.528673, "fiftyDayAverage": 293.5218, "twoHundredDayAverage": 289.26636, "trailingAnnualDividendRate": 9.26, "trailingAnnualDividendYield": 0.03156316, "currency": "USD", "tradeable": false, "enterpriseValue": 206303641600, "profitMargins": 0.18956, "floatShares": 536994412, "sharesOutstanding": 538361984, "sharesShort": 12519619, "sharesShortPriorMonth": 14747690, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0233, "heldPercentInsiders": 0.00214, "heldPercentInstitutions": 0.84062, "shortRatio": 6.48, "shortPercentOfFloat": 0.0233, "impliedSharesOutstanding": 538361984, "bookValue": 13.799, "priceToBook": 21.2856, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": 0.92, "netIncomeToCommon": 6618999808, "trailingEps": 12.22, "forwardEps": 20.67, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 5.908, "enterpriseToEbitda": 12.776, "52WeekChange": -0.10116899, "SandP52WeekChange": 0.1513431, "lastDividendValue": 2.38, "lastDividendDate": 1755820800, "quoteType": "EQUITY", "currentPrice": 293.72, "targetHighPrice": 405.0, "targetLowPrice": 180.0, "targetMeanPrice": 311.34616, "targetMedianPrice": 312.0, "recommendationMean": 2.41935, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 8028000256, "totalCashPerShare": 14.912, "ebitda": 16147999744, "totalDebt": 56204001280, "quickRatio": 0.817, "currentRatio": 1.306, "totalRevenue": 34916999168, "debtToEquity": 756.651, "revenuePerShare": 64.962, "returnOnAssets": 0.07507, "returnOnEquity": 0.99139, "grossProfits": 24217999360, "freeCashflow": 10421999616, "operatingCashflow": 12012999680, "earningsGrowth": 0.92, "revenueGrowth": 0.094, "grossMargins": 0.69359, "ebitdaMargins": 0.46247002, "operatingMargins": 0.32727, "financialCurrency": "USD", "symbol": "AMGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2390388, "fiftyTwoWeekLowChange": 40.42, "fiftyTwoWeekLowChangePercent": 0.15957361, "fiftyTwoWeekRange": "253.3 - 339.17", "fiftyTwoWeekHighChange": -45.450012, "fiftyTwoWeekHighChangePercent": -0.13400362, "fiftyTwoWeekChangePercent": -10.1168995, "dividendDate": 1757635200, "earningsTimestamp": 1754424000, "earningsTimestampStart": 1761768000, "earningsTimestampEnd": 1761768000, "earningsCallTimestampStart": 1754425800, "earningsCallTimestampEnd": 1754425800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 12.22, "epsForward": 20.67, "epsCurrentYear": 21.06522, "priceEpsCurrentYear": 13.943362, "fiftyDayAverageChange": 0.19821167, "fiftyDayAverageChangePercent": 0.00067528774, "twoHundredDayAverageChange": 4.453644, "twoHundredDayAverageChangePercent": 0.015396342, "regularMarketChangePercent": 0.115889, "regularMarketPrice": 293.72, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 424704600000, "postMarketChangePercent": 0.3166256, "postMarketPrice": 294.65, "postMarketChange": 0.9299927, "regularMarketChange": 0.339996, "regularMarketDayRange": "293.3501 - 297.8851", "longName": "Amgen Inc.", "corporateActions": [{"header": "Dividend", "message": "AMGN announced a cash dividend of 2.38 with an ex-date of Aug. 22, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1755835200000, "amount": "2.38"}}], "postMarketTime": 1755906944, "regularMarketTime": 1755892801, "exchange": "NMS", "messageBoardId": "finmb_24816", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Amgen Inc.", "displayName": "Amgen", "trailingPegRatio": 0.9917, "__fetch_time": "2025-08-23"}]